The Department of Health and Human Services yesterday awarded $20.5 million to develop vaccine candidates for Marburg virus and Sudan ebolavirus, which are in the same family of viruses as the Ebola virus outbreak in the Democratic Republic of the Congo. The last outbreaks of Marburg virus and Sudan ebolavirus were in Uganda, in 2017 and 2012, respectively. The Sabin Vaccine Institute will conduct nonclinical studies and complete manufacturing activities to advance the development of the vaccine candidates under a contract with HHS’s Biomedical Advanced Research and Development Authority. BARDA also is helping to develop and procure vaccines, therapeutics and diagnostics for the Ebola strain circulating in the Congo.

Related News Articles

Headline
The Centers for Disease Control and Prevention yesterday joined the World Health Organization to declare the end of the Ebola Virus Disease outbreak in the…
Headline
The Food and Drug Administration yesterday approved the first FDA-approved vaccine to prevent Ebola in adults with Zaire ebolavirus, which killed more…
Headline
A total of 2,291 patients have been hospitalized for vaping-associated lung injuries in the states, Puerto Rico and U.S. Virgin Islands, and 48 people have…
Headline
Achieving the U.S. goal of reducing new HIV infections by 90% over 10 years will require accelerated efforts to diagnose, treat and prevent HIV, according to a…
Headline
A new Centers for Disease Control and Prevention study published today in JAMA Pediatrics reveals that nearly one in five adolescents aged 12-18 years,…
Headline
The Centers for Disease Control and Prevention today released updated guidance to help health care providers diagnose and treat patients with vaping-…